The 4 analysts offering 12-month price forecasts for Cyclacel Pharmaceuticals Inc have a median target of 16.50, with a high estimate of 22.00 and a low estimate of 10.00. The median estimate represents a +1,774.79% increase from the last price of 0.88.
The current consensus among 4 polled investment analysts is to Buy stock in Cyclacel Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.48
Reporting Date Mar 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.